Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Site-specific phosphorylation and caspase cleavage of GFAP are new markers of Alexander disease severity.

Battaglia RA, Beltran AS, Delic S, Dumitru R, Robinson JA, Kabiraj P, Herring LE, Madden VJ, Ravinder N, Willems E, Newman RA, Quinlan RA, Goldman JE, Perng MD, Inagaki M, Snider NT.

Elife. 2019 Nov 4;8. pii: e47789. doi: 10.7554/eLife.47789.


GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.

Bevill SM, Olivares-Quintero JF, Sciaky N, Golitz BT, Singh D, Beltran AS, Rashid NU, Stuhlmiller TJ, Hale A, Moorman NJ, Santos CM, Angus SP, Zawistowski JS, Johnson GL.

Mol Cancer Res. 2019 Jul;17(7):1503-1518. doi: 10.1158/1541-7786.MCR-18-1121. Epub 2019 Apr 18.


Inheritance of OCT4 predetermines fate choice in human embryonic stem cells.

Wolff SC, Kedziora KM, Dumitru R, Dungee CD, Zikry TM, Beltran AS, Haggerty RA, Cheng J, Redick MA, Purvis JE.

Mol Syst Biol. 2018 Sep 3;14(9):e8140. doi: 10.15252/msb.20178140.


Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL.

Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.


Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, Sciaky N, Carey LA, Earp HS, Jin J, Johnson GL.

Cell Rep. 2015 Apr 21;11(3):390-404. doi: 10.1016/j.celrep.2015.03.037. Epub 2015 Apr 9.


Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer.

Stolzenburg S, Beltran AS, Swift-Scanlan T, Rivenbark AG, Rashwan R, Blancafort P.

Oncogene. 2015 Oct;34(43):5427-35. doi: 10.1038/onc.2014.470. Epub 2015 Feb 16.


Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function.

Beltran AS, Graves LM, Blancafort P.

Oncogene. 2014 Sep 25;33(39):4767-77. doi: 10.1038/onc.2013.422. Epub 2013 Oct 21.


Expression of the Pluripotency Transcription Factor OCT4 in the Normal and Aberrant Mammary Gland.

Hassiotou F, Hepworth AR, Beltran AS, Mathews MM, Stuebe AM, Hartmann PE, Filgueira L, Blancafort P.

Front Oncol. 2013 Apr 11;3:79. doi: 10.3389/fonc.2013.00079. eCollection 2013.


Breaking through an epigenetic wall: re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors.

Juárez-Moreno K, Erices R, Beltran AS, Stolzenburg S, Cuello-Fredes M, Owen GI, Qian H, Blancafort P.

Epigenetics. 2013 Feb;8(2):164-76. doi: 10.4161/epi.23503. Epub 2013 Jan 11.


Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors.

Lara H, Wang Y, Beltran AS, Juárez-Moreno K, Yuan X, Kato S, Leisewitz AV, Cuello Fredes M, Licea AF, Connolly DC, Huang L, Blancafort P.

J Biol Chem. 2012 Aug 24;287(35):29873-86. doi: 10.1074/jbc.M112.360768. Epub 2012 Jul 10.


Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer.

Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, Strahl BD, Blancafort P.

Nucleic Acids Res. 2012 Aug;40(14):6725-40. Epub 2012 May 4.


Epigenetic reprogramming of cancer cells via targeted DNA methylation.

Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD, Blancafort P.

Epigenetics. 2012 Apr;7(4):350-60. doi: 10.4161/epi.19507. Epub 2012 Apr 1.


Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor.

Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, Zimmerman E, Graves LM, Blancafort P.

Breast Cancer Res. 2011 Sep 27;13(5):R94. doi: 10.1186/bcr3019.


Suppression of breast tumor growth and metastasis by an engineered transcription factor.

Beltran AS, Russo A, Lara H, Fan C, Lizardi PM, Blancafort P.

PLoS One. 2011;6(9):e24595. doi: 10.1371/journal.pone.0024595. Epub 2011 Sep 13.


Remodeling genomes with artificial transcription factors (ATFs).

Beltran AS, Blancafort P.

Methods Mol Biol. 2010;649:163-82. doi: 10.1007/978-1-60761-753-2_10.


Rational design, selection and specificity of artificial transcription factors (ATFs): the influence of chromatin in target gene regulation.

Blancafort P, Beltran AS.

Comb Chem High Throughput Screen. 2008 Feb;11(2):146-58. Review.


Supplemental Content

Loading ...
Support Center